Drug Profile
Lorukafusp alfa - Apeiron Biologics
Alternative Names: Anti-ganglioside-GD2-antibody-interleukin-2-fusion-protein; APN 301; ch14.18-IL2; EMD 273063; hu14.18-IL2Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Lexigen Pharmaceuticals
- Developer Apeiron Biologics; Merck KGaA; National Cancer Institute (USA); University of Wisconsin-Madison
- Class Antineoplastics; Immunoglobulin fusion proteins; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Malignant melanoma; Neuroblastoma
Most Recent Events
- 19 Jan 2022 University of Wisconsin in collaboration with National Cancer Institute, Bristol-Myers Squibb, Apeiron Biologics and Provenance Biopharmaceuticals suspended the I/II trial in malignant melanoma (Inoperable/Unresectable, Combination therapy, Late-stage disease) in USA, due to administrative decision (Intratumoural) (NCT03958383)
- 29 Jul 2021 University of Wisconsin in collaboration with National Cancer Institute, Bristol-Myers Squibb, Apeiron Biologics and Provenance Biopharmaceuticals reinitiates a phase I/II trial in malignant melanoma (Inoperable/Unresectable, Combination therapy, Late-stage disease) in USA (Intratumoural)(NCT03958383)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Neuroblastoma(Combination therapy, In adolescents, In children, In infants, Second-line therapy or greater, In adults) in USA (IV, Infusion)